Attribution 4.0 International (CC BY 4.0)2022-09-092022-09-092021-09-09Shetty, A. K., Shetty, P. A., Zanirati, G., & Jin, K. (2021). Further validation of the efficacy of mesenchymal stem cell infusions for reducing mortality in COVID-19 patients with ARDS. NPJ Regenerative medicine, 6(1), 53. https://doi.org/10.1038/s41536-021-00161-z2057-3995https://hdl.handle.net/20.500.12503/31697Recent double-blind, randomized, controlled trials reported that human umbilical cord-derived mesenchymal stem cell (MSC) infusions in COVID-19 patients with acute respiratory distress syndrome (ARDS) could diminish cytokine storm and lung damage. While these outcomes are significant, additional phase II/III trials are required to validate the efficacy of MSCs to improve the survival of COVID-19 patients with ARDS. Future studies also need to assess the efficacy of MSCs to prevent long COVID.http://creativecommons.org/licenses/by/4.0/Article© The Author(s) 2021.61